Annual Total Liabilities
$7.66 B
-$93.16 M-1.20%
December 31, 2023
Summary
- As of February 20, 2025, JAZZ annual total liabilities is $7.66 billion, with the most recent change of -$93.16 million (-1.20%) on December 31, 2023.
- During the last 3 years, JAZZ annual total liabilities has risen by +$4.78 billion (+166.20%).
- JAZZ annual total liabilities is now -8.12% below its all-time high of $8.33 billion, reached on December 31, 2021.
Performance
JAZZ Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$8.08 B
+$485.38 M+6.39%
September 30, 2024
Summary
- As of February 20, 2025, JAZZ quarterly total liabilities is $8.08 billion, with the most recent change of +$485.38 million (+6.39%) on September 30, 2024.
- Over the past year, JAZZ quarterly total liabilities has increased by +$369.96 million (+4.80%).
- JAZZ quarterly total liabilities is now -10.98% below its all-time high of $9.08 billion, reached on June 30, 2021.
Performance
JAZZ Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
JAZZ Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -1.2% | +4.8% |
| 3 y3 years | +166.2% | +4.8% |
| 5 y5 years | +213.0% | +4.8% |
JAZZ Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -8.1% | at low | -3.0% | +6.4% |
| 5 y | 5-year | -8.1% | +215.3% | -11.0% | +235.9% |
| alltime | all time | -8.1% | >+9999.0% | -11.0% | >+9999.0% |
Jazz Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $8.08 B(+6.4%) |
| Jun 2024 | - | $7.60 B(-0.4%) |
| Mar 2024 | - | $7.63 B(-0.3%) |
| Dec 2023 | $7.66 B(-1.2%) | $7.66 B(-0.8%) |
| Sep 2023 | - | $7.71 B(-0.3%) |
| Jun 2023 | - | $7.73 B(+0.3%) |
| Mar 2023 | - | $7.71 B(-0.5%) |
| Dec 2022 | $7.75 B(-7.0%) | $7.75 B(+1.4%) |
| Sep 2022 | - | $7.64 B(-4.5%) |
| Jun 2022 | - | $8.00 B(-2.0%) |
| Mar 2022 | - | $8.16 B(-2.1%) |
| Dec 2021 | $8.33 B(+189.7%) | $8.33 B(-2.4%) |
| Sep 2021 | - | $8.54 B(-6.0%) |
| Jun 2021 | - | $9.08 B(+206.9%) |
| Mar 2021 | - | $2.96 B(+2.9%) |
| Dec 2020 | $2.88 B(+18.5%) | $2.88 B(-1.3%) |
| Sep 2020 | - | $2.91 B(-0.3%) |
| Jun 2020 | - | $2.92 B(+21.5%) |
| Mar 2020 | - | $2.41 B(-0.9%) |
| Dec 2019 | $2.43 B(-0.7%) | $2.43 B(-1.8%) |
| Sep 2019 | - | $2.47 B(-1.3%) |
| Jun 2019 | - | $2.51 B(-1.7%) |
| Mar 2019 | - | $2.55 B(+4.2%) |
| Dec 2018 | $2.45 B(+1.5%) | $2.45 B(-0.5%) |
| Sep 2018 | - | $2.46 B(-0.8%) |
| Jun 2018 | - | $2.48 B(-0.9%) |
| Mar 2018 | - | $2.50 B(+3.7%) |
| Dec 2017 | $2.41 B(-17.5%) | $2.41 B(-4.7%) |
| Sep 2017 | - | $2.53 B(-2.8%) |
| Jun 2017 | - | $2.60 B(-8.1%) |
| Mar 2017 | - | $2.83 B(-3.1%) |
| Dec 2016 | $2.92 B(+68.6%) | $2.92 B(-9.1%) |
| Sep 2016 | - | $3.21 B(+83.1%) |
| Jun 2016 | - | $1.76 B(-8.9%) |
| Mar 2016 | - | $1.93 B(+11.2%) |
| Dec 2015 | $1.73 B | $1.73 B(-8.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2015 | - | $1.90 B(-2.3%) |
| Jun 2015 | - | $1.95 B(+0.7%) |
| Mar 2015 | - | $1.93 B(-1.8%) |
| Dec 2014 | $1.97 B(+108.7%) | $1.97 B(-2.0%) |
| Sep 2014 | - | $2.01 B(+7.0%) |
| Jun 2014 | - | $1.88 B(-2.8%) |
| Mar 2014 | - | $1.93 B(+104.7%) |
| Dec 2013 | $942.69 M(+11.5%) | $942.69 M(+0.1%) |
| Sep 2013 | - | $941.80 M(+2.5%) |
| Jun 2013 | - | $918.43 M(+8.3%) |
| Mar 2013 | - | $847.79 M(+0.3%) |
| Dec 2012 | $845.20 M(+1290.5%) | $845.20 M(+0.5%) |
| Sep 2012 | - | $840.61 M(-3.0%) |
| Jun 2012 | - | $866.49 M(+663.2%) |
| Mar 2012 | - | $113.53 M(+86.8%) |
| Dec 2011 | $60.78 M(-42.2%) | $60.78 M(-8.6%) |
| Sep 2011 | - | $66.48 M(-27.6%) |
| Jun 2011 | - | $91.81 M(-2.4%) |
| Mar 2011 | - | $94.11 M(-10.5%) |
| Dec 2010 | $105.18 M(-41.6%) | $105.18 M(-7.4%) |
| Jun 2010 | - | $113.56 M(-35.4%) |
| Mar 2010 | - | $175.70 M(-2.5%) |
| Dec 2009 | $180.23 M(-14.3%) | $180.23 M(-2.4%) |
| Sep 2009 | - | $184.61 M(-6.5%) |
| Jun 2009 | - | $197.47 M(-2.4%) |
| Mar 2009 | - | $202.23 M(-3.9%) |
| Dec 2008 | $210.38 M(+37.9%) | $210.38 M(-3.5%) |
| Sep 2008 | - | $217.97 M(-1.9%) |
| Jun 2008 | - | $222.21 M(-1.9%) |
| Mar 2008 | - | $226.58 M(+48.5%) |
| Dec 2007 | $152.56 M(-61.0%) | $152.56 M(+3.7%) |
| Sep 2007 | - | $147.08 M(-0.5%) |
| Jun 2007 | - | $147.79 M(+21.0%) |
| Mar 2007 | - | $122.09 M(-68.8%) |
| Dec 2006 | $390.87 M(+38.1%) | $390.87 M(+38.1%) |
| Dec 2005 | $283.03 M | $283.03 M |
FAQ
- What is Jazz Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals annual total liabilities year-on-year change?
- What is Jazz Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals quarterly total liabilities year-on-year change?
What is Jazz Pharmaceuticals annual total liabilities?
The current annual total liabilities of JAZZ is $7.66 B
What is the all time high annual total liabilities for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high annual total liabilities is $8.33 B
What is Jazz Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, JAZZ annual total liabilities has changed by -$93.16 M (-1.20%)
What is Jazz Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of JAZZ is $8.08 B
What is the all time high quarterly total liabilities for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high quarterly total liabilities is $9.08 B
What is Jazz Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, JAZZ quarterly total liabilities has changed by +$369.96 M (+4.80%)